Ignite Creation Date:
2025-12-24 @ 3:51 PM
Ignite Modification Date:
2026-01-06 @ 7:15 PM
Study NCT ID:
NCT06182592
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-12-28
First Post:
2023-12-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia
Sponsor:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-01
Start Date Type:
ESTIMATED
Primary Completion Date:
2026-02
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-08
Completion Date Type:
ESTIMATED
First Submit Date:
2023-12-13
First Submit QC Date:
None
Study First Post Date:
2023-12-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-12-27
Last Update Post Date:
2023-12-28
Last Update Post Date Type:
ACTUAL